Details of the Drug

General Information of Drug (ID: DMK8AQP)

Drug Name
Sirukumab
Indication
Disease Entry ICD 11 Status REF
Cutaneous lupus erythematosus EB5Z Phase 3 [1]
Giant cell arteritis 4A44.2 Phase 3 [2]
Rheumatoid arthritis FA20 Phase 3 [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Major depressive disorder 6A70.3 Phase 2 [5]
ATC Code
L04AC15: Sirukumab
L04AC: Interleukin inhibitors
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
640443FU93
DrugBank ID
DB11803
TTD ID
D01XVF
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 6 receptor (IL6R) TT0E5SK IL6RA_HUMAN ; IL6RB_HUMAN Not Available [6]
Interleukin-6 (IL6) TTT1V78 IL6_HUMAN Inhibitor [2]
HUMAN interleukin 6 (IL6) TTJH4Y5 IL6_HUMAN Inhibitor [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cutaneous lupus erythematosus
ICD Disease Classification EB5Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 6 receptor (IL6R) DTT IL6R; IL6ST 1.13E-04 1.32 1.28
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01689532) A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine. U.S. National Institutes of Health.
4 ClinicalTrials.gov (NCT04380961) A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19. U.S. National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
7 Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90.